Shannon Mumenthaler, PhD

Shannon M. Mumenthaler, PhD

Assistant Professor of Medicine
Laboratory Director, Center for Applied Molecular Medicine
Director, Stephenson Family Personalized Medicine Center

+1 323 442 2529
smumenth@usc.edu

Shannon is an Assistant Professor of Medicine at the Keck School of Medicine of USC and the Lab Director for the Lawrence J. Ellison Institute for Transformative Medicine of USC. As Lab Director, Shannon helps guide the scientific planning of the institute, ensure the faculty have the tools they need for their research, and strategize the partnerships and goals of the institute.

Shannon completed her BS in Genetics at UC Davis and then went on to earn a PhD in Cellular and Molecular Pathology at UCLA. Although her primary scientific training is in cell biology, she applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians and engineers to explore critical areas in cancer. Her overall research interest focuses on the importance of the tumor microenvironment in influencing tumor progression and treatment response. She is developing more physiologically-relevant model systems that capture the microenvironmental context of a tumor and coupling these preclinical models with microscopy-based imaging pipelines to provide deeper insights into the evolving tumor. She is inspired by working with colleagues from diverse scientific backgrounds to think outside the box, devise new ways of approaching cancer, create new model systems, and push the limits of cancer research.


Education

BS

2003 Genetics – University of California, Davis, CA

PhD

2008 Cellular and Molecular Pathology – University of California, Los Angeles, CA

Fellowship

2008-2009 Postdoctoral Research Fellow – Louis Warschaw Prostate Cancer Center, Cedars-Sinai, Los Angeles, CA
2009-2012 Postdoctoral Research Associate – Department of Medicine, University of California, Los Angeles, CA


Research Focus

  • Cancer Cell Biology
  • Tumor Microenvironment
  • Drug Resistance

Awards

  • Outstanding Investigator Award, Western American Federation for Medical Research, 2019
  • USC: Undergraduate Research Associates Program (URAP), 2017
  • USC: Rose Hills Fellowship Fund for Undergraduate Research, 2015, 2016, 2018
  • National Cancer Institute: Junior Investigator Award, 2013
  • USC: Medical Faculty Women’s Association Award, 2013
  • UCLA: Hortenese Fishbaugh Memorial Scholarship, 2006-2007
  • UCLA: Life Sciences Core Curriculum Teaching Assistant Honorarium Award, 2005-2006

Publications

Liu X, Lukowski JK, Flinders C, Kim S, Georgiadis RA, Mumenthaler SM, Hummon AB. MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures. Anal Chem. 2018 Dec 18;90(24):14156-14164. doi: 10.1021/acs.analchem.8b02151. View in: PubMed

Chiang CT, Demetriou AN, Ung N, Choudhury N, Ghaffarian K, Ruderman DL, Mumenthaler SM. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Cancer Lett. 2018 Oct 10;434:152-159. doi: 10.1016/j.canlet.2018.07.025. View in: PubMed

Patsch K, Mumenthaler SM, Ruderman D. Image-Based Tracking of Heterogeneous Single-Cell Phenotypes. Methods Mol Biol. 2018;1745:47-63. doi: 10.1007/978-1-4939-7680-5_3. View in: PubMed

Ghaffarizadeh A, Heiland R, Friedman SH, Mumenthaler SM, Macklin P. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. PLoS Comput Biol. 2018 Feb 23;14(2):e1005991. doi: 10.1371/journal.pcbi.1005991. View in: PubMed

Liu X, Flinders C, Mumenthaler SM, Hummon AB. MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids. J Am Soc Mass Spectrom. 2018 Mar;29(3):516-526. doi: 10.1007/s13361-017-1851-4. View in: PubMed

Hudnut AW, Babaei B, Liu S, Larson BK, Mumenthaler SM, Armani AM. Characterization of the mechanical properties of resected porcine organ tissue using optical fiber photoelastic polarimetry. Biomed Opt Express. 2017 Sep 25;8(10):4663-4670. doi: 10.1364/BOE.8.004663. View in: PubMed

Garvey CM, Gerhart TA, Mumenthaler SM. Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques. J Vis Exp. 2017 Jun 30;(124). doi: 10.3791/55844. View in: PubMed

Park SM, Lee JY, Hong S, Lee SH, Dimov IK, Lee H, Suh S, Pan Q, Li K, Wu AM, Mumenthaler SM, Mallick P, Lee LP. Dual transcript and protein quantification in a massive single cell array. Lab Chip. 2016 Oct 7;16(19):3682-8. View in: PubMed

Macklin P, Frieboes HB, Sparks JL, Ghaffarizadeh A, Friedman SH, Juarez EF, Jonckheere E, Mumenthaler SM. Progress Towards Computational 3-D Multicellular Systems Biology. Adv Exp Med Biol. 2016;936:225-246. View in: PubMed

Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. Sci Rep. 2016 Oct 6;6:34785. doi: 10.1038/srep34785. View in: PubMed

Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21;10(1):92. View in: PubMed

Lindsay D, Garvey CM, Mumenthaler SM, Foo J. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol. 2016 Aug 25;12(8):e1005077. View in: PubMed

Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 Jul 25; 6:29752. View in: PubMed

Yadav VK, Smith KS, Flinders C, Mumenthaler SM, De S. Significance of duon mutations in cancer genomes. Sci Rep. 2016; 6:27437. View in: PubMed

Yang-Kolodji G, Mumenthaler SM, Mehta A, Ji L, Tripathy D. Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers. 2015 Jul; 20(5):313-22. View in: PubMed

Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: PubMed

Frieboes HB, Smith BR, Wang Z, Kotsuma M, Ito K, Day A, Cahill B, Flinders C, Mumenthaler SM, Mallick P, Simbawa E, Al-Fhaid AS, Mahmoud SR, Gambhir SS, Cristini V. Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma. PLoS One. 2015; 10(6):e0129433. View in: PubMed

Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET ImmunoPET for Non-Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. View in: PubMed

Foo J, Leder K, Mumenthaler SM. Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evol Appl. 2013 Jan; 6(1):54-69. View in: PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells.
Sci Rep. 2013; 3:1449. View in: PubMed

Mumenthaler SM, D’Antonio G, Preziosi L, Macklin P. The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation. Front Oncol. 2013; 3:194. View in: PubMed

Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 5; 8(6):2069-79. View in: PubMed

Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. View in: PubMed

Villablanca AC, Tenwolde A, Lee M, Huck M, Mumenthaler S, Rutledge JC. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res. 2009 Sep; 2(3):289-99. View in: PubMed

Bernstein HB, Wang G, Plasterer MC, Zack JA, Ramasastry P, Mumenthaler SM, Kitchen CM. CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology. 2009 Apr 25; 387(1):59-66. View in: PubMed

Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW. Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate. 2008 Oct 1; 68(14):1561-9. View in: PubMed

Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW. Expression of arginase II in prostate cancer. Int J Oncol. 2008 Feb; 32(2):357-65. View in: PubMed